Press Releases

Found 271 Results
Page 2 of 28

Onxeo Has Applied for Admission to Trading on Nasdaq First North Growth Market Denmark and Delisting from Nasdaq Main Market Copenhagen

Paris (France), November 27, 2020 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]


Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results

The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients […]



Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors

This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient […]



Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan

Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer […]



Publication of the 2020 Half-Yearly Financial Report

Paris (France), September 29, 2020 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]


Onxeo reports its financial results for the first half of 2020 and provides an update on its activities

The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, […]


Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020

Paris (France), September 8, 2020 – 7:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]


Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States

This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration […]



Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer

DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]



Transfer of the listing of Onxeo securities from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility

Paris (France), July 29, 2020 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]


Page 2 of 28